Summative Usability Study of CEREBO® - a Non Invasive Intracranial Hemorrhage Detector
Sponsored by Bioscan Research Pvt. Ltd.
About this trial
Last updated 3 years ago
Study ID
BR/US/2022/001
Status
Not yet recruiting
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18+ Years
All
Trial Timing
Ended 3 years ago
What is this trial about?
Traumatic brain injury is one of the most common reasons for visits to the Emergency
Department. More than 90% of patients who have suffered from head trauma present with a mild
traumatic brain injury. Most of these patients do not present any symptom at the time of
diagnosis thus delaying the detection. CEREBO®, a non-invasive, portable, rapid,
point-of-care intracranial haemorrhage detector can avoid delayed detection by decreasing the
time from injury to the initial CT scan. The study aims at assessing the summative usability
of the device by determining its ease of use, ease of learning and satisfaction among the
medical health professionals. The participants will be trained before the study and will be
assessed periodically. Each participant will use the device on at least 10 subjects.
What are the participation requirements?
Inclusion Criteria
- Medical health professionals >18 years of age with a valid medical license to practice medicine belonging to one of the following categories and have given a written consent to participate in the study.
- MBBS
- Ayush
- Nurse
- Others Subjects
- Of all ages and gender, have understood the study and gave a written informed consent.
Exclusion Criteria
- Cognitively impaired subjects unable to understand the study procedure